this must be archive.php

FT-2102: Clinical Trial Open to Recruitment

Written by

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

FT-2102

  1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome with an IDH1 R132 mutation
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: FT-2102
  4. Aims and benefits: FT-2102 is an inhibitor of the mutation IDH1, which is seen in 7-14% of
    This is a phase 1/2 study of FT-2102 as a single agent and in combination with azacitidine or low dose cytarabine. The study aims to determine the safety and effectiveness of FT-2102 in this specific patient group.

Read More

Lenalidomide in MDS Patients with Del 5q – Clinical Trial Open to Recruitment

Written by

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

Lenalidomide in MDS Patients with Del 5q

  1. SUB-TYPE OF MDS: Del 5q
  2. SEVERITY OF MDS: Low or Intermediate
  3. NAME OF DRUG: Lenalidomide
  4. Aims and benefits: This trial will investigate how lenalidomide, Revlimid®, affects the disease progression of patients with transfusion dependent MDS. This is a registry, non-interventional study.

Read More

Rigosertib Intravenous – INSPIRE – Clinical Trial Open to Recruitment

Written by

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

Rigosertib Intravenous

  1. SUB-TYPE OF MDS: All.
  2. SEVERITY OF MDS: All.
  3. NAME OF DRUG: Rigosertib
  4. Aims and benefits: This trial will investigate the survival of MDS patients receiving intravenous Rigosertib after failure of treatment with a Hypomethylating agent (HMA), Azacitidine (aza) or Decitabine (DEC)

Read More

LI-1 – Clinical Trial Open to Recruitment

Written by

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

LI-1

    1. SUB-TYPE OF MDS: MDS with 10% or more bone marrow blasts and also acute myeloid leukaemia
    2. SEVERITY OF MDS: Intermediate –2 or High Risk
    3. NAME OF DRUG: AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Lenalidomide and other novel therapies that will become available throughout the course of the study. These are all target treatments that block various pathways in the proliferation or growth of leukaemia cells.

Read More

AML 19 – Clinical Trial Open to Recruitment

Written by

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

AML 19

  1. SUB-TYPE OF MDS: MDS with 10% bone marrow blasts OR more; also acute myeloid leukaemia
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Mylotarg, CPX-351 (a novel drug which combines two anti-cancer drugs - cytarabine and daunorubicin in a new formulation)

Read More

AML 18 – Clinical Trial Open to Recruitment

Written by

MDS Patient Support

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

AML 18

    1. SUB-TYPE OF MDS: MDS with 10% or more bone marrow blasts; also acute myeloid leukaemia
    2. SEVERITY OF MDS: Intermediate – 2 or High Risk
    3. NAME OF DRUG: Mylotarg, AC220 (a novel drug that blocks the action of a gene – FLT3, which is important in the growth of blood cells

Read More

Free donations by shopping